Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CONCERT PHARMACEUTICALS, INC. (CNCE) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/06/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Contingent Value Rights Agreement, by and among Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries Ltd., Computershare Inc. and Computershare Trust Company, N.A",
"Second Amended and Restated By-Laws"
01/19/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Sun Pharmaceutical Industries Ltd., Foliage Merger Sub, Inc. and Concert Pharmaceuticals, Inc",
"Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata"
11/07/2022 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata"
08/22/2022 8-K Other Events  Interactive Data
08/04/2022 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata",
"Creating New Possibilities for Patients to Live Their Lives August 2022"
06/13/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
02/03/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update"
11/08/2021 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series X1 Preferred Stock",
"Form of Warrant",
"Opinion of Goodwin Procter, LLP",
"Securities Purchase Agreement",
"Concert Pharmaceuticals Announces $65 Million Financing"
08/05/2021 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results CTP-543 Phase 3 Program On Track to Support NDA Filing in Early 2023"
06/11/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
12/11/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "SECOND AMENDMENT TO AMENDED AND RESTATED BY-LAWS"
11/05/2020 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update"
10/30/2020 8-K Other Events  Interactive Data
08/06/2020 8-K Quarterly results
06/12/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/30/2020 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs Conference Call Scheduled Today at 8:30 a.m. ET"
02/27/2020 8-K Quarterly results
01/28/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "4,752,420 Shares Pre-Funded Warrants to Purchase 1,800,000 Shares Concert Pharmaceuticals, Inc. UNDERWRITING AGREEMENT January 28, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022",
"CONCERT PHARMACEUTICALS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] Warrant No. [ ] Original Issue Date: January [__], 2020 Concert Pharmaceuticals, Inc., a Delaware corporation , hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Perceptive Life Sciences Master Fund, LTD, or its permitted registered assigns , is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [___] shares of common stock, $0.001 par value per share , of the Company at an exercise price per share equal to $0.001 per share , upon surrender of this Warrant to Purchase Common Stock at any time and from time to time on or after the date hereof , subject to the following terms ...",
"Re: Securities Registered under Registration Statement on Form S-3",
"Concert Pharmaceuticals Announces Pricing of Public Offering"
01/22/2020 8-K Other Events
11/07/2019 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update Conference Call Scheduled Today at 8:30 a.m. ET"
10/30/2019 8-K Quarterly results
09/05/2019 8-K Other Events
Docs: "CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata September 3, 2019"
08/01/2019 8-K Quarterly results
Docs: "Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update Conference Call Scheduled Today at 8:30 a.m. EDT"
06/17/2019 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy